Table 4.
(A) T category | |||||||||
8-TNM | Total | ||||||||
T1a | T1b | T1c | T2a | T2b | T3 | T4 | |||
7-TNM | T1a | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 5 (7.8%) |
T1b | 0 | 0 | 3 | 4 | 1 | 0 | 0 | 8 (12.5%) | |
T2a | 0 | 0 | 4 | 3 | 3 | 0 | 0 | 10 (15.6%) | |
T2b | 0 | 0 | 0 | 0 | 1 | 7 | 0 | 8 (12.5%) | |
T3 | 0 | 0 | 1 | 1 | 4 | 5 | 5 | 16 (25%) | |
T4 | 0 | 0 | 0 | 0 | 0 | 2 | 15 | 17 (26.6%) | |
Total | 2 (3.1%) | 3 (4.7%) | 8 (12.5%) | 8 (12.5%) | 9 (14.1%) | 14 (21.9%) | 20 (31.3%) | ||
(B) Stage group | |||||||||
8-TNM | Total | ||||||||
IB | IIB | IIIA | IIIB | IIIC | |||||
7-TNM | IB | 1 | 0 | 0 | 0 | 0 | 1 (1.6%) | ||
IIA | 0 | 1 | 0 | 0 | 0 | 1 (1.6%) | |||
IIB | 0 | 1 | 2 | 0 | 0 | 3 (4.7%) | |||
IIIA | 0 | 1 | 18 | 10 | 0 | 29 (45.3%) | |||
IIIB | 0 | 0 | 0 | 22 | 8 | 30 (46.9%) | |||
Total | 1 (1.6%) | 3 (4.7%) | 20 (31.3%) | 32 (50%) | 8 (12.5%) |
7-TNM seventh American Joint Committee on Cancer TNM staging system, 8-TNM eighth American Joint Committee on Cancer TNM staging system